<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00805285</url>
  </required_header>
  <id_info>
    <org_study_id>H-30365</org_study_id>
    <nct_id>NCT00805285</nct_id>
  </id_info>
  <brief_title>The Use of Oral Budesonide and Rectal Hydrocortisone for the Treatment of Active Ulcerative Colitis</brief_title>
  <official_title>Oral Budesonide and Rectal Hydrocortisone for the Treatment of Extensive Ulcerative Colitis: A Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Maryland, Baltimore</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Maryland, Baltimore</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate if the combination of oral budesonide and rectal&#xD;
      hydrocortisone improves symptoms in patients with active ulcerative colitis. Also, we would&#xD;
      like to determine if oral budesonide and rectal hydrocortisone has fewer and less severe side&#xD;
      effects compared to standard steroids (prednisone).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Ulcerative colitis (UC) is a common chronic inflammatory condition of the intestines that&#xD;
      results in bloody diarrhea, abdominal pain, and extraintestinal manifestations of disease.&#xD;
      The disease course is typically chronic, characterized by periodic exacerbations followed by&#xD;
      symptom- free intervals; less commonly symptoms are continuous and unrelenting. The symptoms&#xD;
      and disease course have a profound, detrimental impact on the quality of life in patients&#xD;
      with UC.&#xD;
&#xD;
      The initial therapeutic approach depends upon both the extent of colonic involvement and the&#xD;
      severity of the disease process at presentation. Typically, patients are treated based on a&#xD;
      pyramid or &quot;Step up&quot; approach. If patients have mild symptoms, they receive less powerful&#xD;
      therapies lower in the pyramid with fewer side effects. Patients with disease confined to&#xD;
      distal colon are typically treated with topical therapies including either 5-ASA or steroid&#xD;
      enemas. However, as symptoms worsen or if severe at the time of diagnosis, patients receive&#xD;
      more aggressive therapies higher in the pyramid including steroids. Despite medical therapy,&#xD;
      50% will have colectomy or become steroid dependent one year after receiving steroids.&#xD;
&#xD;
      Steroids are associated with significant side effects. Adverse consequences of steroids are&#xD;
      related to dose and duration of exposure, and include but are not limited to cosmetic side&#xD;
      effects, ocular disease (glaucoma, cataracts), diabetes, hypertension, vascular disease,&#xD;
      osteoporosis, neuropsychiatric complications, and increased risk of infection.&#xD;
&#xD;
      Newer &quot;designer&quot; corticosteroids including budesonide have reduced systemic bioavailability&#xD;
      and high local anti-inflammatory activity; as a result it is associated with fewer and less&#xD;
      severe side effects. Studies have proven the efficacy of budesonide in inducing remission in&#xD;
      active Crohn's disease. However, the data for the use of oral budesonide in patients with UC&#xD;
      is less extensive. However, the data regarding the efficacy of topical therapy for left-sided&#xD;
      UC is extensive. Randomized controlled trials of budesonide enemas have demonstrated similar&#xD;
      efficacy and safety profile to hydrocortisone enemas in the induction of remission of left&#xD;
      sided UC. We have chosen to utilize hydrocortisone enemas in our study as it is widely&#xD;
      available in the United States.&#xD;
&#xD;
      A 52-week open-label pilot study will be performed at the University of Maryland Medical&#xD;
      Center. Subjects will include patients with previously or newly diagnosed extensive&#xD;
      ulcerative colitis. Patients will be treated with oral budesonide and rectal hydrocortisone&#xD;
      for 8 weeks followed by a predetermined taper. All patients will undergo research clinic&#xD;
      visits at enrollment and week 8. During these visits, patients will complete a series of&#xD;
      questionnaires that measure the patient's disease activity, quality of life, side effects,&#xD;
      medical compliance, and other parameters. Blood draws and stool studies are required at each&#xD;
      study visit to monitor blood counts, electrolytes, liver function, inflammatory markers, and&#xD;
      adrenal function. Additionally, at week 16, an ACTH (cosyntropin) stimulation test will be&#xD;
      performed. After obtaining a basal cortisol level, 250 ug of cosyntropin is given&#xD;
      intravenously. Plasma samples of cortisol will then be drawn at 30 minutes to assess for&#xD;
      adrenal insufficiency. Close follow-up with eight 30-min telephone sessions (every 2-3 weeks)&#xD;
      will also be conducted to assess disease activity and adverse events.&#xD;
&#xD;
      The goal of this study is to determine whether combination therapy using oral budesonide and&#xD;
      topical hydrocortisone will result in the induction of remission in patients with active&#xD;
      extensive ulcerative colitis. Further, we aim to show that combination therapy is better&#xD;
      tolerated and has less severe side effects compared to conventional therapy with prednisone.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Study terminated due to insufficient enrollment&#xD;
  </why_stopped>
  <start_date>October 2008</start_date>
  <completion_date type="Actual">March 2010</completion_date>
  <primary_completion_date type="Actual">October 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Simple Clinical Colitis Disease Activity (SCCAI)</measure>
    <time_frame>0, 2, 4, 6, and 8 weeks</time_frame>
    <description>Scores range from 0-19. Higher scores indicated increased disease severity. A score less than 3 is consistent with clinical remission.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Short Inflammatory Bowel Disease Questionnaire (SIBDQ)</measure>
    <time_frame>Week 0 and 8</time_frame>
    <description>Scores range from 10-70 where higher scores indicated better quality of life.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>ACTH Stimulation Test</measure>
    <time_frame>Week 16</time_frame>
    <description>An increase in cortisol after stimulation by ACTH is normal. Blood cortisol after ACTH stimulation should be greater than 18 - 20 mcg/dL, depending on the dose of cosyntropin used.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>0, 2, 4, 6, 8, 11, 14, 20, 26, and 52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>C Reactive Protein</measure>
    <time_frame>Week 0 and 8</time_frame>
    <description>Higher values indicated increased disease activity</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">1</enrollment>
  <condition>Inflammatory Bowel Disease</condition>
  <condition>Ulcerative Colitis</condition>
  <arm_group>
    <arm_group_label>Combination Oral Budesonide and Rectal Hydrocortisone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>See intervention</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Combination Oral Budesonide and Rectal Hydrocortisone</intervention_name>
    <description>Budesonide 9 mg PO (oral) daily and hydrocortisone 100 mL PR (enema) for an 8-week period. The doses of each drug to be used in the pilot study are standard doses used in clinical practice. After 8-weeks, the budesonide will be tapered in the following manner: 1) budesonide 6 mg PO daily and hydrocortisone 100 ml PR every other day (EOD) for 3 weeks then 2) budesonide 3 mg PO daily and hydrocortisone 100 ml PR 2 x per week for 3 weeks then 3) discontinue budesonide.</description>
    <arm_group_label>Combination Oral Budesonide and Rectal Hydrocortisone</arm_group_label>
    <other_name>Entocort</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Written, voluntary, informed consent given&#xD;
&#xD;
          -  18 years or older&#xD;
&#xD;
          -  Speak and read English&#xD;
&#xD;
          -  Extensive ulcerative colitis based upon endoscopy, histopathology, and clinical&#xD;
             symptoms&#xD;
&#xD;
          -  SCCAI Score &gt; 3&#xD;
&#xD;
          -  Presence of diarrhea (3 or more bowel movements per 24 hours) AND grossly visible&#xD;
             blood in stool&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Serum creatinine &gt; 2.0 mg/dL&#xD;
&#xD;
          -  Pregnant or breastfeeding&#xD;
&#xD;
          -  Prior history of total or subtotal colectomy, or currently has an ostomy&#xD;
&#xD;
          -  History or suspicion of Crohn's disease or Indeterminate colitis&#xD;
&#xD;
          -  Diagnosis of any condition deemed by the investigator inhibiting completion of the&#xD;
             trial&#xD;
&#xD;
          -  Initiated therapy with or change in mesalamine dose within the last 4 weeks&#xD;
&#xD;
          -  Change in azathioprine, 6-mercaptopurine, or cyclosporine within the last 8 weeks&#xD;
&#xD;
          -  Currently taking or have used corticosteroids within the last 8 weeks&#xD;
&#xD;
          -  Rectally administered mesalamine or steroids within the last 2 weeks&#xD;
&#xD;
          -  Current or prior use of anti-TNF alpha agents within the last 8 weeks&#xD;
&#xD;
          -  Experimental ulcerative colitis agents within the last 8 weeks&#xD;
&#xD;
          -  Concomitant use of CYP3A4 activity inhibitor (e.g. ketoconazole, itraconazole,&#xD;
             ritonavir, indinavir, erythromycin)&#xD;
&#xD;
          -  Uncontrolled diabetes (HgA1c &gt; 8.0) within 1 year&#xD;
&#xD;
          -  Unstable Coronary artery disease/Class III/IV CHF&#xD;
&#xD;
          -  Decompensated cirrhosis (e.g. encephalopathy, renal failure, ascites, GIB)&#xD;
&#xD;
          -  Any known infection requiring antibiotics&#xD;
&#xD;
          -  Active Clostridium difficile infection&#xD;
&#xD;
          -  COPD requiring home oxygen&#xD;
&#xD;
          -  HIV/AIDS with CD4 &lt; 200 or AIDs-defining illnesses/infections&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Raymond K Cross, MD, MS</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Maryland, College Park</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Leyla J Ghazi, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Maryland, College Park</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Maryland</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.umm.edu/ibd/research.htm</url>
    <description>University of Maryland IBD Program</description>
  </link>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>December 8, 2008</study_first_submitted>
  <study_first_submitted_qc>December 8, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 9, 2008</study_first_posted>
  <results_first_submitted>January 24, 2013</results_first_submitted>
  <results_first_submitted_qc>March 30, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 13, 2013</results_first_posted>
  <last_update_submitted>November 25, 2019</last_update_submitted>
  <last_update_submitted_qc>November 25, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 4, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Maryland, Baltimore</investigator_affiliation>
    <investigator_full_name>Raymond Cross</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Inflammatory Bowel Disease</keyword>
  <keyword>Ulcerative Colitis</keyword>
  <keyword>Budesonide</keyword>
  <keyword>Corticosteroids</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colitis</mesh_term>
    <mesh_term>Colitis, Ulcerative</mesh_term>
    <mesh_term>Intestinal Diseases</mesh_term>
    <mesh_term>Inflammatory Bowel Diseases</mesh_term>
    <mesh_term>Ulcer</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Budesonide</mesh_term>
    <mesh_term>Hydrocortisone</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Combination Oral Budesonide and Rectal Hydrocortisone</title>
          <description>Budesonide 9 mg po daily and Rectal Hydrocortisone once daily</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The only enrolled patient was withdrawn secondary to disease worsening.</population>
      <group_list>
        <group group_id="B1">
          <title>Combination Oral Budesonide and Rectal Hydrocortisone</title>
          <description>Intervention Arm</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="1"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Simple Clinical Colitis Disease Activity (SCCAI)</title>
        <description>Scores range from 0-19. Higher scores indicated increased disease severity. A score less than 3 is consistent with clinical remission.</description>
        <time_frame>0, 2, 4, 6, and 8 weeks</time_frame>
        <population>The only patient enrolled withdrew; there was no data to analyze.</population>
        <group_list>
          <group group_id="O1">
            <title>Combination Oral Budesonide and Rectal Hydrocortisone</title>
            <description>Intervention Arm</description>
          </group>
        </group_list>
        <measure>
          <title>Simple Clinical Colitis Disease Activity (SCCAI)</title>
          <description>Scores range from 0-19. Higher scores indicated increased disease severity. A score less than 3 is consistent with clinical remission.</description>
          <population>The only patient enrolled withdrew; there was no data to analyze.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Short Inflammatory Bowel Disease Questionnaire (SIBDQ)</title>
        <description>Scores range from 10-70 where higher scores indicated better quality of life.</description>
        <time_frame>Week 0 and 8</time_frame>
        <population>The only patient enrolled withdrew; there was no data to analyze.</population>
        <group_list>
          <group group_id="O1">
            <title>Combination Oral Budesonide and Rectal Hydrocortisone</title>
            <description>Intervention Arm</description>
          </group>
        </group_list>
        <measure>
          <title>Short Inflammatory Bowel Disease Questionnaire (SIBDQ)</title>
          <description>Scores range from 10-70 where higher scores indicated better quality of life.</description>
          <population>The only patient enrolled withdrew; there was no data to analyze.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>ACTH Stimulation Test</title>
        <description>An increase in cortisol after stimulation by ACTH is normal. Blood cortisol after ACTH stimulation should be greater than 18 - 20 mcg/dL, depending on the dose of cosyntropin used.</description>
        <time_frame>Week 16</time_frame>
        <population>The only patient enrolled withdrew; there was no data to analyze.</population>
        <group_list>
          <group group_id="O1">
            <title>Combination Oral Budesonide and Rectal Hydrocortisone</title>
            <description>Intervention Arm</description>
          </group>
        </group_list>
        <measure>
          <title>ACTH Stimulation Test</title>
          <description>An increase in cortisol after stimulation by ACTH is normal. Blood cortisol after ACTH stimulation should be greater than 18 - 20 mcg/dL, depending on the dose of cosyntropin used.</description>
          <population>The only patient enrolled withdrew; there was no data to analyze.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adverse Events</title>
        <time_frame>0, 2, 4, 6, 8, 11, 14, 20, 26, and 52 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Combination Oral Budesonide and Rectal Hydrocortisone</title>
            <description>Intervention Arm</description>
          </group>
        </group_list>
        <measure>
          <title>Adverse Events</title>
          <units>Adverse events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>C Reactive Protein</title>
        <description>Higher values indicated increased disease activity</description>
        <time_frame>Week 0 and 8</time_frame>
        <population>The only patient enrolled withdrew; there was no data to analyze.</population>
        <group_list>
          <group group_id="O1">
            <title>Combination Oral Budesonide and Rectal Hydrocortisone</title>
            <description>Intervention Arm</description>
          </group>
        </group_list>
        <measure>
          <title>C Reactive Protein</title>
          <description>Higher values indicated increased disease activity</description>
          <population>The only patient enrolled withdrew; there was no data to analyze.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Combination Oral Budesonide and Rectal Hydrocortisone</title>
          <description>Intervention Arm</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Worsening of ulcerative colitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Portal vein and superior mesenteric vein thrombosis</sub_title>
                <description>The only enrolled patient was found to have a portal and superior mesenteric vein thrombosis. This was thought to be related to the underlying ulcerative colitis and not related to the intervention.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The study was terminated early by the University of Maryland HRPO secondary to limited recruitment of participants. This resulted in an inability to analyze the results.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Raymond Cross, MD, MS</name_or_title>
      <organization>University of Maryland, Baltimore</organization>
      <phone>410-706-3387</phone>
      <email>rcross@medicine.umaryland.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

